RT Journal Article
T1 Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
A1 Piñana, José Luis
A1 Sanz, Jaime
A1 Picardi, Alessandra
A1 Ferrá, Christelle
A1 Martino, Rodrigo
A1 Barba, Pere
A1 Gonzalez-Vicent, Marta
A1 Pascual, María Jesús
A1 Martín, Carmen
A1 Verdeguer, Amparo
A1 Diaz de Heredia, Cristina
A1 Montesinos, Pau
A1 Ribera, José-María
A1 Sanz, Miguel
A1 Arcese, William
A1 Sanz, Guillermo
K1 Aloinjertos
K1 Enfermedad crónica
K1 Trasplante de células madre de la sangre del cordón
K1 Supervivencia sin Enfermedad
K1 Estudios de Seguimiento
K1 Enfermedad injerto contra huésped
K1 Agonistas mieloablativos
K1 Cromosoma Filadelfia
K1 Leucemia-linfoma linfoblástico de células precursoras
K1 Estudios retrospectivos
K1 Tasa de Supervivencia
K1 Acondicionamiento para el trasplante
AB There are very few disease-specific studies focusing on outcomes of umbilical cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. We report the outcome of 45 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent myeloablative single unit cord blood transplantation from unrelated donors within the GETH/GITMO cooperative group. Conditioning regimens were based on combinations of thiotepa, busulfan, cyclophospamide or fludarabine, and antithymocyte globulin. At the time of transplantation, 35 patients (78%) were in first complete remission, four (8%) in second complete remission and six (14%) in third or subsequent response. The cumulative incidence of myeloid engraftment was 96% at a median time of 20 days and significantly better for patients receiving higher doses of CD34(+) cells. The incidence of acute grade II-IV graft-versus-host disease was 31%, while that of overall chronic graft-versus-host disease was 53%. Treatment-related mortality was 17% at day +100 and 31% at 5 years. The 5-year relapse, event-free survival and overall survival rates were 31%, 36% and 44%, respectively. Although the event-free and overall survival rates in patients without BCR/ABL transcripts detectable at time of transplant were better than those in whom BCR/ABL transcripts were detected (46% versus 24% and 60% versus 30%, respectively) these differences were not statistically significant in the univariate analysis (P=0.07). These results demonstrate that umbilical cord blood transplantation from unrelated donors can be a curative treatment for a substantial number of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
PB Ferrata Storti Foundation
SN 0390-6078
YR 2014
FD 2014-02
LK http://hdl.handle.net/10668/1838
UL http://hdl.handle.net/10668/1838
LA en
NO Piñana JL, Sanz J, Picardi A, Ferrá C, Martino R, Barba P, et al. Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2014; 99(2):378-84
NO Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 8, 2025